Evidence Level:Sensitive: C1 - Off-label
(Approved for Non Small Cell Lung Cancer)
New
Title:
Mirati Therapeutics Receives Approval from the MHRA for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation
Excerpt:Mirati Therapeutics...announced the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) granted conditional marketing authorization approval for KRAZATI® (adagrasib) as a monotherapy indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with KRASG12C mutation and have progressive disease after prior therapy with, or intolerance to, platinum-based chemotherapy and/or anti-PD-1/PD-L1 immunotherapy.
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)
Excerpt:...- Histologically confirmed diagnosis of a solid tumor malignancy with KRAS G12C mutation (phase 1b must be either Non-Small Cell Lung Cancer or Colorectal Cancer)...
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Excerpt:...- Phase 2: Histologically confirmed diagnosis of unresectable or metastatic NSCLC with KRAS G12C mutation and any PD-L1 TPS...
More C2 evidence
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
Excerpt:...- Have advanced NSCLC or metastatic NSCLC (NSCLC that started in the lungs and then spread to other parts of the body) with the KRAS G12C mutation....
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
A Phase 1/2 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway
Excerpt:...MRTX0902 and adagrasib combination therapy: KRAS G12C mutation....
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)
Excerpt:...- Histologically confirmed diagnosis of a solid tumor malignancy with KRAS G12C mutation (phase 2 must be either Non-Small Cell Lung Cancer or Colorectal Cancer)...
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
Adagrasib in Combination With Palbociclib in Patients With Advanced Solid Tumors (KRYSTAL-16)
Excerpt:...- Histologically confirmed diagnosis of a solid tumor malignancy with KRAS G12C mutation...
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation
Excerpt:...- KRASG12C-mutated solid malignancy determined by a sponsor-approved assay using either tumor tissue or ctDNA....
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
Adagrasib in Patients With KRASG12C-mutant NSCLC Who Are Elderly or Have Poor Performance Status
Excerpt:...KRASG12C-mutation by local testing (by tissue or ctDNA)....
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation
Excerpt:...Cohort A* (closed): Has an untreated and unresectable or metastatic NSCLC with histologically confirmed (squamous or nonsquamous) KRASG12C mutation and histologically confirmed PD-L1 TPS ≥1%....
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
Phase Ib Trial of the KRASG12C Inhibitor Adagrasib (MRTX849) in KRAS G12C Mutant Metastatic Pancreatic Cancer Patients
Excerpt:...Histologically confirmed diagnosis of a pancreatic cancer with KRAS G12C mutation....
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation (KRYSTAL -19)
Excerpt:...- Histologically confirmed diagnosis of solid tumor malignancy (Phase 1) or NSCLC (Phase 2) with KRAS G12C mutation...
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
Excerpt:...- Histologically confirmed diagnosis of a solid tumor malignancy with KRAS G12C mutation...
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation
Excerpt:...- Histologically or cytologically confirmed diagnosis of NSCLC with KRAS G12C mutation....
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
Expanded Access of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors Who Have a KRAS G12C Mutation
Excerpt:...- Confirmed presence of a KRASG12C mutation...
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
The Clinical Trial to Evaluate the Pharmacokinetics and Safety of MRTX849 in Patients With Advanced Solid Tumors
Excerpt:...Histologically confirmed diagnosis of a solid tumor malignancy with KRAS G12C mutation....
Less C2 evidence
Evidence Level:Sensitive: C3 – Early Trials
Title:
Adagrasib in Advanced Solid Tumors Harboring a KRASG12C Mutation
Excerpt:Among 57 patients with measurable disease at baseline, objective responses were observed in 20 (35.1%) patients (all partial responses), including 7/21 (33.3%) responses in pancreatic and 5/12 (41.7%) in biliary tract cancers....Adagrasib demonstrates encouraging clinical activity and is well tolerated in this rare cohort of pretreated patients with KRASG12C-mutated solid tumors.
